E Groopman - JoVE Visualize

Showing results (171-180 of 208) with videos related to

Pageof 21

Sort By:

The New England Journal of Medicine|December 12, 1985

Intra-blood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complexL Resnick, F diMarzo-Veronese, J Schüpbach, et al.

Lancet (London, England)|December 22, 1984

HTLV-III in symptom-free seronegative personsS Z Salahuddin, J E Groopman, P D Markham, et al.

Proceedings of the National Academy of Sciences of the United States of America|July 1, 1988

Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120P W Berman, J E Groopman, T Gregory, et al.

Journal of Acquired Immune Deficiency Syndromes|March 1, 1993

Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials GroupM A Fischl, S E Krown, K P O'Boyle, et al.

JAMA|September 11, 1987

Suramin therapy in AIDS and related disorders. Report of the US Suramin Working GroupB D Cheson, A M Levine, D Mildvan, et al.

Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1985

Isolation and functional analysis of human B cell populations. I. Characterization of the B1+B2+ and B1+B2- subsetsK C Anderson, A W Boyd, D C Fisher, et al.

Annals of Internal Medicine|January 1, 1985

Apparent transmission of human T-cell leukemia virus type III to a heterosexual woman with the acquired immunodeficiency syndromeJ E Groopman, M G Sarngadharan, S Z Salahuddin, et al.

Nature|February 9, 1989

Designing CD4 immunoadhesins for AIDS therapyD J Capon, S M Chamow, J Mordenti, et al.

Annals of Internal Medicine|May 1, 1984

Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndromeJ E Groopman, M S Gottlieb, J Goodman, et al.

Journal of Virology|May 1, 1997

Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vectorR T Inouye, B Du, D Boldt-Houle, et al.

Pageof 21

Showing results (171-180 of 208) with videos related to

Sort By:

Pageof 21

The New England Journal of Medicine|December 12, 1985

Intra-blood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complexL Resnick, F diMarzo-Veronese, J Schüpbach, et al.

Lancet (London, England)|December 22, 1984

HTLV-III in symptom-free seronegative personsS Z Salahuddin, J E Groopman, P D Markham, et al.

Proceedings of the National Academy of Sciences of the United States of America|July 1, 1988

Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120P W Berman, J E Groopman, T Gregory, et al.

Journal of Acquired Immune Deficiency Syndromes|March 1, 1993

Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials GroupM A Fischl, S E Krown, K P O'Boyle, et al.

JAMA|September 11, 1987

Suramin therapy in AIDS and related disorders. Report of the US Suramin Working GroupB D Cheson, A M Levine, D Mildvan, et al.

Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1985

Isolation and functional analysis of human B cell populations. I. Characterization of the B1+B2+ and B1+B2- subsetsK C Anderson, A W Boyd, D C Fisher, et al.

Annals of Internal Medicine|January 1, 1985

Apparent transmission of human T-cell leukemia virus type III to a heterosexual woman with the acquired immunodeficiency syndromeJ E Groopman, M G Sarngadharan, S Z Salahuddin, et al.

Nature|February 9, 1989

Designing CD4 immunoadhesins for AIDS therapyD J Capon, S M Chamow, J Mordenti, et al.

Annals of Internal Medicine|May 1, 1984

Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndromeJ E Groopman, M S Gottlieb, J Goodman, et al.

Journal of Virology|May 1, 1997

Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vectorR T Inouye, B Du, D Boldt-Houle, et al.

Pageof 21